Diabetic Kidney Disease (DKD) is a leading cause of chronic kidney disease (CKD) in the US.

Not all adult type 2 diabetics develop CKD and progress to kidney failure requiring dialysis or transplant.

The American Diabetes Association (ADA) and Kidney Disease:

Improving Global Outcomes (KDIGO) recommend annual measurement of urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) for all adult patients with type 2 diabetes.

We utilize KidneyIntelX technology (Renalytix) to assess the risk of progressive decline in kidney function in individuals with early-
stage (CKD stages 1 through 3B) diabetic kidney disease (DKD).

Renalytix is an artificial intelligence-enabled (AI) blood test that utilizes biomarkers, genetic data, and patient information to assess the risk of diabetic kidney disease (DKD) progression.

Renalytix generates a risk score that categorizes patients into low, moderate, or elevated risk for progressive decline in kidney function.

Renalytix helps to identify patients at higher risk of progression, allowing for earlier intervention personalized care and potentially reducing the progression to end-stage kidney disease (ESKD)

At NY Kidney & Hypertension Medicine (NYKHM), we are dedicated to bringing the latest medical innovations to our communities, enabling patients with chronic kidney disease to take charge of their health and wellness.

The KidneyIntelX.dkd test enables us and our patients to understand kidney disease risk early, allowing us to take timely
action and deliver the most effective care available today. Diabetic Kidney Disease (DKD) is a leading cause of chronic kidney disease (CKD) in the US.